Community/Retail

The POETYK PSO-1 and POETYK PSO-2 trials, which evaluated deucravacitinib 6 mg once daily, met both co-primary endpoints versus placebo, with significantly more patients achieving Psoriasis Area and Severity Index (PASI) 75 response and a static Physician's Global Assessment score of clear or almost clear (sPGA 0/1) after 16 weeks of treatment with deucravacitinib.

Kristen Lund

Just as pharmacists have been on the front lines of the COVID-19 pandemic, Kristen Lund, CPhT, a technician at Hy-Vee Pharmacy in Harlan, Iowa, said technicians have taken on greater responsibilities and have become more involved in patient care.